Whitehawk Therapeutics (WHWK) Gross Profit (2021 - 2025)

Whitehawk Therapeutics (WHWK) has reported Gross Profit for 5 consecutive years, with $6.4 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Gross Profit rose 35.82% year-over-year to $6.4 million; the TTM figure through Dec 2025 stood at $6.4 million (down 72.19% YoY), while the FY2025 annual figure was $6.4 million, down 72.19% from the prior year.
• Gross Profit eased to $6.4 million in Q1 2025 per WHWK's latest filing, from $6.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $14.0 million in Q4 2021 and bottomed at $2.1 million in Q1 2022.
• Historically, Gross Profit has averaged $5.6 million across 5 years, with a median of $5.4 million in 2023.
• Annual changes were most pronounced in 2022 — Gross Profit plunged 64.25% — and 2023, when it soared 150.85%.
• Whitehawk Therapeutics' Gross Profit stood at $14.0 million in 2021, then slumped by 64.25% to $5.0 million in 2022, then advanced by 7.87% to $5.4 million in 2023, then climbed by 19.45% to $6.4 million in 2024, then retreated by 0.99% to $6.4 million in 2025.
• Business Quant data shows WHWK's Gross Profit at $6.4 million in Q1 2025, $6.4 million in Q4 2024, and $6.4 million in Q3 2024.